Peptides for injury recovery: what the evidence shows
A pulled hamstring feels better in two weeks. An Achilles tendon can nag for a year. The difference is plumbing, and that is exactly where the recovery peptides act.
Free to join · One email when peptide care opens · Most lab results in 3–5 business days
The answer, in short
The main peptides studied for injury recovery are BPC-157, TB-500 and its parent protein thymosin beta-4. They help new blood vessels form and draw repair cells into damaged tissue. BPC-157 has three decades of positive animal studies but one small human knee report. Thymosin beta-4 has human trials in the eye, skin and heart, none in sports injuries.
Medically reviewed by Robert Lufkin, MD (opens in a new tab)
Chief Medical Officer, Vitals Vault · Updated · 21 sources
Why some injuries heal fast and others drag on
Anyone who has had both a muscle strain and a tendon problem knows they live on different clocks. A bruised thigh muscle is usually forgotten in a week or two. An elbow or Achilles tendon can stay sore for months, improving and relapsing with every return to activity.
The reason is supply. Healing tissue can only rebuild as fast as oxygen, nutrients and repair cells arrive, and they arrive by blood. Muscle is packed with blood vessels and cells. Tendons and ligaments are engineered for tensile strength and carry few of either. Researchers call them hypovascular and hypocellular, and that thin supply line is the main reason they heal slowly.
Repair also needs movement at the cellular level. Fibroblasts, the cells that lay down new collagen, and endothelial cells, which build new vessels, have to crawl into the injured area. They do it by constantly building and dismantling actin, the protein scaffolding inside every cell. And the whole process runs through a stage of inflammation that has to switch on and then, crucially, switch off.
Blood supply, cell movement and inflammation are the three levers the recovery peptides pull. That is both their appeal and the key to reading their evidence honestly.267
How the recovery peptides act
BPC-157 is a 15-amino-acid fragment of a protective protein found in gastric juice. Its most consistent effect in animal research is on angiogenesis, the growth of new small vessels from existing ones. It also raises how many growth hormone receptors cells carry and lowers inflammatory cytokines, the chemical alarms that keep inflammation going. Its developers add effects on the lining of blood vessels and on nitric oxide, which controls blood flow.
Thymosin beta-4 is a 43-amino-acid protein present in almost every cell. Its day job is holding actin in reserve. In human platelets it holds at least half of the cell’s spare actin. By releasing that actin where it is needed, it helps repair cells move into a wound. It also supports new vessel growth and protects stressed cells, and in mice after a heart attack it improved heart muscle survival and function.
TB-500 is a seven-amino-acid piece of thymosin beta-4, the actin-binding site. In NIH cell studies, that short motif matched the full protein’s ability to drive vessel-lining cells to migrate and sprout, while fragments missing part of it were inactive. It does not carry the front end of the protein, which holds most of the anti-scarring activity.14687910
Recovery peptides compared
Each peptide in this chapter with the best evidence it has. The third column is where they differ most.
| Peptide | How it works | Best evidence | Evidence level |
|---|---|---|---|
| BPC-157 | New blood vessels, more growth hormone receptors, less inflammation | 35 animal studies of muscle, tendon, ligament and bone; one 12-person knee report | Early research |
| TB-500 | Actin-binding fragment of thymosin beta-4; cell movement, new vessels | Cell studies; no human trials of the fragment itself | Early research |
| Thymosin beta-4 | Full protein: cell movement, new vessels, cell protection, less scarring | Phase III eye trial: 6 of 10 healed vs 1 of 8 (not significant) | Human trials |
BPC-157: a consistent signal in animals
In 2003, a team in Zagreb cut rats’ Achilles tendons all the way through and followed healing for two weeks. Tendons treated with BPC-157 withstood more load before failing, the rats walked better, and the tissue laid down more collagen. By 2019, a review in Cell and Tissue Research found that every study the authors could identify showed consistent, prompt healing, with the most promise in tendon and ligament.
The most complete map came in 2025. A systematic review in HSS Journal screened 544 articles and kept 36: 35 animal studies and one clinical report. Across the animal models, BPC-157 improved function, tissue structure and load-bearing strength after muscle, tendon, ligament and bone injuries. Improvement on all three measures is more convincing than a tidy microscope slide alone.
The single clinical report involved knees. Seven of 12 people with long-term knee pain reported relief lasting more than six months after one injection into the joint. There was no comparison group. BPC-157 also has a half-life of under 30 minutes, which suggests that if it works, it works as a starting signal for repair rather than something that has to stay in the blood. The 2025 review found no clinical safety data, and most of the research comes from a small number of groups.321
TB-500 and thymosin beta-4: the parent has the trials
Thymosin beta-4 is unusual among recovery peptides because it has been through formal human trials. In a phase I study, 40 healthy volunteers tolerated intravenous doses with no dose-limiting toxicity. In a small phase 2 dry eye trial, eye drops of the protein cut discomfort by 35.1 percent and corneal staining by 59.1 percent compared with vehicle.
Its largest test so far was a phase III trial in 18 adults with neurotrophic keratopathy, a hard-to-heal corneal wound. Six of 10 people on thymosin beta-4 drops healed at four weeks, against 1 of 8 on placebo. Comfort improved significantly, but the healing difference missed statistical significance. A 2025 heart attack trial in 96 adults found a smaller damaged area when the first dose was given within eight hours, with no significant difference across the whole group.
TB-500 borrows almost all of that evidence. Every one of those trials tested the full 43-amino-acid protein as eye drops, skin gels or infusions. TB-500, the seven-amino-acid fragment sold for injuries, has no published human trials of its own. And thymosin beta-4 has also been studied for its role in tumor metastasis and new vessel growth in cancer, which is the theoretical concern with any peptide that builds blood supply.13141516912
The injury in the study is rarely the injury in your knee
Here is the detail most discussions of healing peptides skip. The classic BPC-157 tendon study cut a healthy rat tendon clean through. That is an acute injury in a young animal, the situation where a fresh blood supply is exactly what the tissue needs. Most people asking about peptides have something different, a tendon that has been overloaded for months and never quite settled.
Chronic tendon pain has its own biology, and blood vessels play a strange role in it. In a 2015 Copenhagen trial, 58 people with Achilles tendinopathy lasting more than three months did 12 weeks of either eccentric exercise or heavy, slow resistance training. Both groups improved, the gains held at one year, and as symptoms got better the abnormal new vessels in the tendon decreased. In that setting, recovery came with fewer vessels.
That does not mean a vessel-building peptide is wrong for a chronic tendon. Nobody has tested it. It does mean the rat transection data answer a different question from the one most readers have, and the most reliable treatment for chronic tendon pain in a randomized trial is still progressive loading. The thymosin beta-4 trials add a parallel lesson. Its human evidence comes from eyes, skin and hearts, and its developers name ligament and spinal cord repair only as future targets.31711
What else moves the same system, and what to measure
Load is the signal that tells tendon what to rebuild. Both the eccentric and heavy slow resistance programs in the Copenhagen trial produced lasting improvement, and compliance was higher with heavy slow resistance, 92 percent against 78 percent. Whatever else you add, a graded loading plan from a physical therapist is the part with the strongest evidence.
The supply line still matters. Protein provides the building material for collagen, and sleep is when much of the body’s repair signaling runs. The BPC-157 animal research adds a twist for anyone taking anti-inflammatory painkillers. In experimental models, it counteracted gut and other damage from NSAIDs, the common drugs people reach for when a tendon aches.
Labs make a peptide course measurable. BPC-157 is broken down by the liver and cleared by the kidneys, so ALT and eGFR are sensible baselines. hs-CRP reflects inflammation anywhere in the body and gives a clinician general context. Vitamin D is common to check after a bone or tendon injury and easy to correct when low.1751
Safety and the quality problem
In animals, the safety record is reassuring. Preclinical studies of BPC-157 found no adverse effects across several organ systems, and few of the studies in the 2019 review reported adverse reactions at all. Full-length thymosin beta-4 was well tolerated in its phase I trial in healthy volunteers. What nobody has measured is long-term use in people, and FDA’s April 2026 compounding safety page notes how little human safety information exists for these substances.
The more immediate risk is often the vial. The 2025 BPC-157 review lists unregulated manufacturing and contamination alongside unknown clinical safety. A peptide is only as clean as the facility that made it, which is why a prescription filled by a licensed compounding pharmacy is a different product from a vial sold online for research use.
Some people should take the question to a clinician before anything else: anyone with liver or kidney disease, anyone pregnant or breastfeeding, anyone with a history of cancer, because these peptides encourage new blood vessel growth, and anyone in tested sport.21131912
Where these stand in 2026
Since October 29, 2026, FDA allows 503A compounding pharmacies to prepare BPC-157 and TB-500 for individual patients with a prescription, under enforcement discretion while a final rule is pending. Neither is FDA-approved. No thymosin beta-4 drug is approved either, and an eye drop version is in a phase 3 trial. All three are prohibited in tested sport.20191821
What this means for you
The recovery peptides act on real bottlenecks in healing: blood supply, cell movement and inflammation. BPC-157 has a long, consistent record in animals and almost none in people. Thymosin beta-4 has real human trials, in eyes, skin and hearts. TB-500 sits between them, a fragment that carries part of its parent’s activity and none of its human data.
The best question to ask a clinician is what kind of injury you have. A fresh tear in poorly supplied tissue is closest to what the animal studies modeled. A tendon that has ached for months is closer to the Copenhagen trial, where structured loading did the work. Either way, a peptide is an add-on to rehab, and a before-and-after blood panel is how you and your clinician keep it honest.11517
Start with your labs
A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment.
- TestA baseline panel at Quest Diagnostics.
- DecideA licensed clinician reviews your history and results.
- RetestThe same markers again, side by side.
- Liver enzymes (ALT)Part of a metabolic panel. Checks the liver before and during any new prescription.
- Kidney function (eGFR)Peptides are cleared through the kidneys, so a baseline is useful.
- hs-CRPA blood marker of inflammation you can track before and after a course.
- Vitamin D (25-OH)Commonly checked after bone and tendon injuries, and easy to correct when low.
Questions
What is the best peptide for injury recovery?
BPC-157 has the largest body of injury research, mostly in rats, with the most promise in tendon and ligament. Thymosin beta-4 has more human trials, but in eyes, skin and the heart. Neither has large human trials for sports injuries.
Do peptides help tendons heal?
In rats, BPC-157 helped fully cut Achilles tendons heal stronger and faster. In people, the evidence is one small knee report without a control group. For chronic tendon pain, structured loading has the strongest trial evidence.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a seven-amino-acid fragment of the 43-amino-acid protein. It keeps the actin-binding site but not the front end linked to anti-scarring effects, and the human trials used the full protein.
Can you take BPC-157 and TB-500 together?
Many people do, because they act through different repair routes. No study has tested the two together, so a clinician should decide whether the combination suits you.
How fast do healing peptides work?
The human data are thin. In the knee report, people who improved described relief lasting more than six months after one injection. Animal tendon studies measured healing over about two weeks.
Are healing peptides safe?
Animal studies of BPC-157 report few adverse effects, and thymosin beta-4 was well tolerated in a phase I trial. Long-term human safety is unmeasured, and vials sold online as research chemicals are not made for people.
Should people with a cancer history use healing peptides?
They should ask a clinician first. These peptides encourage new blood vessel growth, which tumors also use, and thymosin beta-4 has been studied for its role in tumor spread.
Are recovery peptides banned in sport?
Yes. BPC-157, TB-500 and thymosin beta-4 are all prohibited by the World Anti-Doping Agency, and anti-doping labs can detect TB-500 in urine and plasma.
Peptides, prescribed and measured
Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first.
- Prescription only
- Licensed US clinicians
- Quest Diagnostics labs
Keep reading
Full Peptide Guide- BPC-157A 15-amino-acid peptide from a stomach protein, studied for tendon, muscle and gut repair.
- TB-500A seven-amino-acid piece of thymosin beta-4, the repair protein studied for wounds, eyes and the heart.
- Thymosin beta-4The full 43-amino-acid repair protein behind TB-500, tested in eye, skin and heart trials.
- BPC-157 vs TB-500How the two most popular recovery peptides differ, and why people take them together.
- Peptides for muscle growthGrowth hormone releasers, IGF-1 variants and myostatin blockers: what each does to muscle, and what the human trials measured.
- FDA peptide update 2026What FDA’s October 2026 decision on six peptides means for you.
Sources
- 1. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025 (opens in a new tab)
- 2. Gwyer D, et al. BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019 (opens in a new tab)
- 3. Staresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003 (opens in a new tab)
- 4. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL 14736). Inflammopharmacology. 2006 (opens in a new tab)
- 5. Sikiric P, et al. Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013 (opens in a new tab)
- 6. Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991 (opens in a new tab)
- 7. Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003 (opens in a new tab)
- 8. Bock-Marquette I, et al. Thymosin beta4 promotes cardiac cell migration, survival and cardiac repair. Nature. 2004 (opens in a new tab)
- 9. Esposito S, et al. The N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012 (opens in a new tab)
- 10. Kleinman HK, et al. Thymosin β4 and the anti-fibrotic switch. Int Immunopharmacol. 2023 (opens in a new tab)
- 11. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015 (opens in a new tab)
- 12. Cha HJ, et al. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003 (opens in a new tab)
- 13. Ruff D, et al. Intravenous thymosin beta4 in healthy volunteers: phase I. Ann N Y Acad Sci. 2010 (opens in a new tab)
- 14. Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 (opens in a new tab)
- 15. Sosne G, et al. RGN-259 (thymosin β4) eye drops in neurotrophic keratopathy: phase III trial. Int J Mol Sci. 2022 (opens in a new tab)
- 16. Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025 (opens in a new tab)
- 17. Beyer R, et al. Heavy slow resistance versus eccentric training as treatment for Achilles tendinopathy: a randomized controlled trial. Am J Sports Med. 2015 (opens in a new tab)
- 18. ClinicalTrials.gov. NCT05555589. RGN-259 ophthalmic solution for neurotrophic keratopathy (SEER-2), recruiting (opens in a new tab)
- 19. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of April 22, 2026) (opens in a new tab)
- 20. NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)
- 21. World Anti-Doping Agency. Prohibited List (opens in a new tab)